)
Visual
test
Insmed
Insmed (INSM) investor relations material
Insmed 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Strategic vision and business development
Focused on three therapeutic areas: respiratory, immunology and inflammation, and neuro/rare, with flexibility to expand if compelling opportunities arise.
Emphasis on developing first- and best-in-class therapies, with continued investment in R&D and business development to drive future value.
Ambition to create a self-sustaining biotech, emphasizing pipeline growth and proactive business development.
Willingness to pursue new therapeutic areas beyond current focus if high-impact opportunities are identified.
Product performance and pipeline highlights
BRINSUPRI launched strongly, with over 11,550 patients and 4,000 prescribers in its first full quarter, generating $144.6M in Q4 2025 U.S. net revenues.
ARIKAYCE generated $433.8M worldwide in FY 2025, with 2026 guidance set at $450–$470M and international revenues up 40.9%.
TPIP advancing with four parallel phase 3 programs; early data in PH-ILD and PAH show best-in-class efficacy.
INS1148, a first-in-class monoclonal antibody, added to the pipeline for respiratory, IBD, ILD, and asthma indications, set to enter Phase 2 trials in 2026.
Clinical development and future milestones
Multiple clinical readouts expected, including ARIKAYCE ENCORE Phase 3 (March/April 2026), TPIP Phase 3, and BRINSUPRI in HS (CEDAR trial) in Q2 2026.
Next-gen DPP-1 inhibitors entering trials for RA and IBD, supported by strong animal model data.
Gene therapy programs for DMD, ALS, and Stargardt disease progressing, with key IND filings and trial updates anticipated in 2026–2027.
Impact of BRINSUPRI payor contract finalization
ENCORE trial's impact on ARIKAYCE TAM
INS1148 first-in-class potential
BRINSUPRI comorbid patient opportunity?
TPIP PPF/IPF trial manufacturing/regulatory?
Gene therapy data timeline for DMD/ALS/Stargardt?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebTUPRS
Net income rose to TRY 29.5 billion, with strong cash position and major dividend payout. - 6 FebCPT
2025 results beat guidance; Sun Belt focus, asset sales, and share buybacks drive 2026 strategy. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and strategic spin-offs for future growth. - 6 FebCRIH1 2025 saw a return to profit, record revenues, and strong cash from major space projects.
- 6 FebSCW
Q2 2025 revenue up 120% y/y, driven by record Asian contract and backlog growth. - 6 FebSCWRevenue up 89% y/y, record backlog, and new strategy for European optical payload leadership.
- 6 FebSCWQ2 2024 revenue up 115% y/y, backlog nearly doubled, driven by major space contracts.
- 6 FebSCWSpace segment drives 29% revenue growth, strong backlog and contracts support 2025 outlook.
- 6 FebSCW73% revenue growth, record backlog, and major space contracts drive expansion and investment.
- 6 FebPENG
All proposals passed, with no questions raised and results to be filed on Form 8-K.
Next Insmed earnings date
Q4 202519 Feb, 2026
Insmed
Next Insmed earnings date
Q4 202519 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for rare and serious diseases. The company’s research areas include pulmonary conditions, inflammatory diseases, and genetic disorders. It serves patients through approved therapies and a clinical development pipeline. The company is headquartered in Bridgewater, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage